Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics. The agreement, centred on the development of RNA ...

Sangamo Therapeutics has stacked up $18 million cash from Eli ... deal that will let the pharma use the biotech's neurotropic adeno-associated virus capsid in efforts to develop a gene therapy ...

Eli Lilly signaled its growing ... The partnership Lilly and Verve began over the summer covers an in vivo gene-editing therapy that offers the potential for a one-time treatment for reducing ...

Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness. The AK-OTOF therapy ...

Eli Lilly hasn’t been ... the opportunity to develop the first gene therapy for hearing loss. Lilly has agreed to acquire Akouos in a $487 million deal that comes a month after the FDA cleared ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly and Company LLY announced a ... Akouos’ shares were up 88% on Tuesday in response to the deal with Lilly. In the gene therapy field, Lilly acquired Prevail Therapeutics in 2021 that ...

Oct 18 (Reuters) - Eli ... gene therapies for sensorineural hearing loss, soared 84% to trade 40 cents above Lilly's offer price of $12.50 before the opening bell. Sign up here. The deal also ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey there. So, today we talk about how Eli Lilly’s gene therapy ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly is strengthening its position ... The therapy is part of Lilly’s broader push into gene therapy. In April 2025, Lilly inked a deal worth $1.4bn with Sangamo Therapeutics to develop ...